Clinical trials: Acute Myeloid Leukemia (AML) With
Leukemia, Myeloid, Acute
Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Acute Myeloid Leukemia (AML) Adult Patients
This is a IIa phase IIa open-label, non-randomized clinical trial of Antroquinonol, capsule, 100 mg (Golden Biotechnology Corporation, Taiwan) in patients with AML.
- Trial name
- NCT03823352
- Testing
- Antroquinonol
- Where
- 2 sites in Russia
- Volunteers
- 12 people
- Sponsor
- Golden Biotechnology Corporation
Acute Myeloid Leukemia
Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia
The study is to evaluate safety, tolerability and composite CR of IBI188 plus Demethylating Agents in acute myeloid leukemia
- Trial name
- NCT04485052
- Testing
- IBI188, Azacitidine, Decitabine
- Where
- China
- Volunteers
- 222 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Leukemia, Myeloid, Acute
AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia
This study is a phase I/II study to determine the safety and efficacy of AMD3100 when combined with mitoxantrone, etoposide, and cytarabine in patients with relapsed or refractory AML.
- Trial name
- AMD3100+MEC (NCT00512252)
- Testing
- AMD3100, Mitoxantrone, Etoposide
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Washington University School of Medicine
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
Recent studies of conventional chemotherapy for infants with high-risk hematologic malignancies show that the long-term disease-free survival is low.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplasia, Chronic Myeloid Leukemia
- Trial name
- NCT00145626
- Testing
- Chemotherapy and antibodies, Miltenyi Biotec CliniMACS, Allogeneic stem cell transplantation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- St. Jude Children's Research Hospital
Breast Cancer, Chronic Myeloproliferative Disorders
Campath-1H + FK506 and Methylprednisolone for GVHD
RATIONALE: Alemtuzumab, tacrolimus, and methylprednisolone may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00109993
- Testing
- alemtuzumab, methylprednisolone, tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Leukemia, Acute Myeloid Leukemia
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
This study is a phase Ib/II study of Max-40279-01 in combination with Azacitidine (AZA) in patients with Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML).
- Conditions
- Leukemia, Acute Myeloid Leukemia, Relapsed/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT05061147
- Testing
- MAX-40279-01
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Maxinovel Pty., Ltd.
Leukemia, Myeloid, Acute
Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia
The purpose of the study is to characterize safety and tolerability of cusatuzumab in combination with various therapies used to treat acute myeloid leukemia (AML).
- Trial name
- ELEVATE (NCT04150887)
- Testing
- Cusatuzumab, Azacitidine, Venetoclax
- Where
- 23 sites in United States, Canada and 3 more
- Volunteers
- 61 people
- Sponsor
- OncoVerity, Inc.
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
This phase Ib trial tests the safety, side effects, and best dose of a enasidenib in combination with cobimetinib in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment…
- Trial name
- NCT05441514
- Testing
- Cobimetinib, Enasidenib Mesylate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- City of Hope Medical Center
Acute Myeloid Leukemia
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
This phase II trial tests how well ziftomenib works in treating patients with NPM1 mutated or KMT2A rearranged acute myeloid leukemia (AML) and are not eligible to receive standard therapy.
- Trial name
- NCT06930352
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Uma Borate
Acute Myeloid Leukemia
Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients
This is a single-arm, Phase II study of crenolanib as maintenance in AML patients with FLT3 mutations who have achieved complete remission (CR) after allogeneic stem cell transplantation.
- Trial name
- NCT02400255
- Testing
- Crenolanib besylate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Collecting and Storing Blood Samples From Patients With Cancer
RATIONALE: Collecting and storing samples of blood from patients with cancer to test in the laboratory may help the study of cancer in the future.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00900120
- Sponsor
- University of Medicine and Dentistry of New Jersey
Acute Myelogenous Leukemia
Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia
The purpose of this study is to determine whether bortezomib in combination with doxil/lipodox is effective in the treatment of Acute Myeloid Leukemia.
- Trial name
- NCT01736943
- Testing
- Bortezomib, Doxil
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Joseph Tuscano
Acute Myelogenous Leukemia
Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)
The purpose of the Phase 1b dose finding phase is to determine the safety, tolerability, and maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of TAK-659 in participants with relapsed or refractory AML.
- Trial name
- NCT02323113
- Testing
- TAK-659
- Where
- 17 sites in United States, Canada
- Volunteers
- 43 people
- Sponsor
- Calithera Biosciences, Inc
Acute Myeloid Leukemia (AML), Leukemic Dendritic Cell Vaccination
Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia
This is an open label phase 1 feasibility and safety dose escalation study. The main objective is to evaluate the safety of DCP-001 intradermal vaccination in patients with AML.
- Trial name
- NCT01373515
- Testing
- DCP-001
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Mendus
Acute Myeloid Leukemia
RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR
Elderly patients with acute myeloid leukemia (AML) often face unfavorable prognostic factors such as multiple comorbidities, adverse cytogenetic profiles, and pre-existing hematological disorders.
- Trial name
- NCT06571825
- Testing
- Venetoclax, Allogeneic transplant
- Where
- China
- Volunteers
- 118 people
- Sponsor
- He Huang
Secondary Acute Myeloid Leukemia
Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia
This phase Ib/II trial finds out the best dose and effect of cladribine and low dose cytarabine when given in combination with uproleselan in treating patients with treated secondary acute myeloid leukemia.
- Trial name
- NCT04848974
- Testing
- Cladribine, Cytarabine, Uproleselan
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
ACUTE MYELOID LEUKEMIA; AML
A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia
This is a phase 1b/2 study. All patients are diagnosed with Acute Myeloid Leukemia (AML), Eastern Cooperative Oncology Group (ECOG) performance status 0-3.
- Trial name
- NCT06387420
- Testing
- AK117, Azacitidine, Venetoclax
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Akeso
Leukemia
VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as VNP40101M and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00354276
- Testing
- cytarabine, laromustine
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 85 people
- Sponsor
- Vion Pharmaceuticals
Leukemia, Myeloid, Acute, Refractory AML
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with…
- Conditions
- Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome With Excess Blasts-2
- Trial name
- TUSCANY (NCT03850574)
- Testing
- Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion
- Where
- 34 sites in United States, Australia and 4 more
- Volunteers
- 240 people
- Sponsor
- Aptose Biosciences Inc.
High Risk Acute Myeloid Leukemia
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia
To confirm the efficacy of CPX-351 compared to 7+3 as first line therapy in elderly patients (60-75 yrs) with high risk (secondary) Acute Myeloid Leukemia. The primary efficacy endpoint will be overall survival.
- Trial name
- 301 (NCT01696084)
- Testing
- CPX-351, 7+3 (cytarabine and daunorubicin)
- Where
- 43 sites in United States, Canada
- Volunteers
- 309 people
- Sponsor
- Jazz Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.